1. Partnering Deals and Alliances with Big Pharma
The Partnering Deals and Alliances with Big Pharma report provides the most comprehensive and in-depth
insight into the dealmaking interests and activity of the worlds leading fifty big pharma companies.
Partnering Deals and Alliances with Big Pharma provides the user with the following key benefits:
Detailed partnering activity profiles for each of the top 50 big pharma companies Over 300 charts showing a
company’s dealmaking activity since 2005, allowing quick identification potential partners Partnering
therapy focus revealed Partnering activity since 2005 – number of deals per year Full listing of
partnering deals Activity by deal type Activity by industry sector Activity by phase of development Activity
by technology type Activity by therapeutic area Comprehensive access to over 3,000 partnering deals as
recorded at Current Agreement, together with contract documents if available Insight into the terms included
in a partnering agreement, together with real world clause examples, via contract documents Understand the
key deal terms the company has agreed in previous deals Undertake due diligence to assess suitability of your
proposed deal terms for partner companies
The Partnering Deals and Alliances with Big Pharma report provides the most comprehensive and in-depth
insight into the dealmaking interests and activity of the worlds leading fifty big pharma companies.
This premier report provides all the information you require to better understand big pharma partnering.
One of the key aspects of partnering is finding those companies that are potential candidates for the
development and commercialization of the next generation of therapies. A lot of resources are spent on finding
partners, identifying their interests and making contact to initiate discussions.
Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the
company’s business development objectives. Over 300 charts allow quick understanding of each big
pharma companies dealmaking trends over the last four years.
This report contains over 3,000 links to online copies of actual partnering deals as recorded at Current
Agreement, together with contract documents if submitted to the Securities Exchange Commission by
bigpharma and their partners.
Contract documents provide the answers to numerous questions about a prospective partner’s
flexibility on a wide range of important issues, many of which will have a significant impact on each
party’s ability to derive value from the deal.
The initial chapters of this report provide an orientation of bigpharma’s dealmaking and business
activities.
Chapter 1 provides an introduction to the report, whilst
Chapter 2 lists the top 50 leading big pharma companies based on 2011 pharmaceutical revenues and
dealmaking activity since 2005.
Chapter 3 reviews the top deals of 2005-2013 according to reported deal size.
Chapter 4 provides a summary on best practice on how to submit an opportunity to big pharma, to ensure
building of relationships and to obtain a prompt assessment and response from the business development
function of the prospective partner.
Chapter 5 lists forthcoming partnering events where valuable face to face meetings with bigpharma provide a
highly effective means of obtaining interest in novel opportunities. These events are where dealmaking gets
Partnering Deals and Alliances with Big Pharma

2. initiated through numerous back to back meetings.
The main body of the report is provided in chapter 6. In-depth profiles of every big pharma company provide
everything required to assess the suitability of a company as a prospective partner. Each profile includes a
company overview, partnering activity according to deal type, industry sector, phase of development, therapy
area and technology type.
Each company profile provides a comprehensive listing of deal records available at Current Agreements, each
of which links direct to an online copy of the actual deal record plus contract document if filed with the SEC.
Key benefits
Partnering Deals and Alliances with Big Pharma provides the user with the following key benefits:
Detailed partnering activity profiles for each of the top 50 big pharma companies Over 300 charts showing a
company’s dealmaking activity since 2005, allowing quick identification potential partners Partnering
therapy focus revealed Partnering activity since 2005 – number of deals per year Full listing of
partnering deals Activity by deal type Activity by industry sector Activity by phase of development Activity
by technology type Activity by therapeutic area Comprehensive access to over 3,000 partnering deals as
recorded at Current Agreement, together with contract documents if available Insight into the terms included
in a partnering agreement, together with real world clause examples, via contract documents Understand the
key deal terms the company has agreed in previous deals Undertake due diligence to assess suitability of your
proposed deal terms for partner companies Report scope
Partnering Deals and Alliances with Big Pharma is intended to provide the reader with an in-depth
understanding of the partnering activities of the leading fifty big pharma companies worldwide, enabling the
effective assessment and selection of partners of choice, based on the latest knowledge of a company’s
partnering.
Partnering Deals and Alliances with Big Pharma includes:
Detailed company profiles for each of the top 50 big pharma companies, including: Partnering interests and
indications Partnering activity since 2005 Partner companies since 2005 Partnering activity since 2005 by:
Partner company Deal type Industry sector Stage of development Technology type Therapy area Over 300
charts showing the dealmaking activity of each company since 2005 The tools to enable effective and efficient
preparation for partnering negotiation with big pharma 3,000 partnering deals as recorded at Current
Agreement, together with contract documents if available The leading M&A and partnering deals by value
2005-2012
The Partnering Deals and Alliances with Big Pharma report also provides comprehensive access to available
contract documents for each of the fifty big pharma companies.
Analyzing actual company agreements allows assessment of the following:
What is actually granted by the agreement to the partner company? What exclusivity is granted? What is the
payment structure for the deal? How are sales and payments audited? What is the deal term? How are the key
terms of the agreement defined? How are IPRs handled and owned? Who is responsible for
commercialization? Who is responsible for development, supply, and manufacture? How is confidentiality and
publication managed? How are disputes to be resolved? Under what conditions can the deal be terminated?
What happens when there is a change of ownership? What sublicensing and subscontracting provisions have
been agreed? Which boilerplate clauses does the company insist upon? Which boilerplate clauses appear to
differ from partner to partner or deal type to deal type? Which jurisdiction does the company insist upon for
agreement law?
Partnering Deals and Alliances with Big Pharma

3. table Of Content
executive Summary
chapter 1 – Introduction
chapter 2 – Big Pharma Top 50 Dealmaking Activity
2.1. Introduction
2.2. Big Pharma Partnering Over The Years
2.4. Big Pharma Partnering By Deal Type
2.5. Big Pharma Partnering Industry Sector
2.6. Big Pharma Partnering By Stage Of Development
2.7. Big Pharma Partnering By Technology Type
2.8. Big Pharma Partnering By Therapy Area
2.9. Big Pharma M&a Over The Years
chapter 3 – Top Big Pharma Deals By Value
3.1. Introduction
3.2. Big Pharma Partnering
3.3. Big Pharma M&a
chapter 4 – Submitting Opportunities To Big Pharma
4.1. How To Submit An Opportunity
4.2. Opportunity Submission Template
4.3. Sending Emails
4.4. Face To Face At Partnering Events
4.5. Online Submission Forms
chapter 5 – Forthcoming Big Pharma Partnering Events
5.1. Forthcoming Events
chapter 6 – Big Pharma Company Profiles
6.1. Introduction
6.2. Field Definitions
6.3. Company Profiles
abbott
Partnering Deals and Alliances with Big Pharma

4. actavis (formerly Watson Pharmaceuticals)
actelion
allergan
amgen
aspen Pharmacare
astellas
astrazeneca
baxter International
bayer
biogen Idec
boehringer Ingelheim
bristol-myers Squibb
celgene
csl
daiichi Sankyo
dainippon Sumitomo
eisai
eli Lilly
endo Pharmaceuticals
forest Laboratories
galderma
gilead Sciences
glaxosmithkline
grifols
hospira
johnson & Johnson / Janssen
kyowa Hakko Kirin
lundbeck
menarini
merck & Co
merck Kgaa
mitsubishi Tanabe
mylan
novartis
novo Nordisk
otsuka
pfizer
purdue Pharma
roche
sanofi
sanofi-aventis
servier
shionogi
Partnering Deals and Alliances with Big Pharma

5. shire
takeda
teva
ucb
valeant Pharmaceuticals
warner Chilcott
chapter 7 – Resources
appendices
appendix 1 – Deal Type Definitions
appendix 2 – Example Contract Document
about Wildwood Ventures
current Partnering
current Agreements
current Reports
recent Titles From Currentpartnering
order Form – Reports
About Us:
Transparency Market Research is a market intelligence company providing global business information
reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides
forward-looking insight for thousands of decision makers. We are privileged with highly experienced team of
Analysts, Researchers and Consultants, who use proprietary data sources and various tools and techniques to
gather, and analyze information. Our business offerings represent the latest and the most reliable information
indispensable for businesses to sustain a competitive edge.
Contact:
ResearchMoz
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-997-4948
Email: sales@researchmoz.us
Blog: http://researchmoz.blogspot.com/
Website: http://www.researchmoz.us/
Partnering Deals and Alliances with Big Pharma